Biomarkers of metastatic melanoma

Biomarkers in Medicine

Volumn 3, Issue 1, 2009, Pages 71-89

  Neagu, Monica ^a   Constantin, Carolina ^a   Manda, Gina ^a   Margaritescu, Irina ^b  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b Central Military Hospital Bucharest   (Romania)

Author keywords

Antitumor response; Melanin synthesis metabolites; Melanoma markers; Metastasis; MIA; S 100B; Skin melanoma

Indexed keywords

ANGIOGENIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; C REACTIVE PROTEIN; CERULOPLASMIN; COPPER; CYSTEINYLDOPA; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ERYTHROPOIETIN; GROWTH FACTOR; INTERLEUKIN 8; INTERMEDIN; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MELAN A; MELANIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; ONCOPROTEIN; PROTEIN S 100; PROTEIN YKL 40; RECEPTOR PROTEIN; SIALIC ACID; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZINC;

AUTOCRINE EFFECT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LABORATORY TEST; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA CELL; METABOLITE; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

EID: 68049092859     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.3.1.71     Document Type: Review

References (161)

1. Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182 (2006).
2. McKenna DB, Stockton D, Brewster DH, Doherty VR: Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br. J. Cancer 88, 74-78 (2003).
3. Rezaul K, Wilson LL, Han DK: Direct tissue proteomics in human diseases: potential applications to melanoma research. Expert Rev. Proteomics. 5(3), 405-412 (2008).
4. Jemal A, Clegg LX, Ward E et al.: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101, 3-27 (2004).
5. Morton DL, Hsueh EC, Essner R et al.: Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Sur. 236(4), 438-449 (2002).
6. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 6(274), 1703-1705 (1995).
7. Balch CM: Cutaneous melanoma: prognosis and treatment results worldwide. Semin. Surg. Oncol. 8, 400-414 (1992).
8. Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J: Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio. J. Med. 57(1), 57-64 (2008).
9. Grizzi F, Chiriva-Internati M: Cancer: looking for simplicity and finding complexity Review. Cancer Cell Int. 6, 4-10 (2006).
10. Moellmann G, Mcguire J, Lerner AB: Ultrastructure and cell biology of pigment cells, intracellular dynamics and the fine structure of melanocytes with special reference to the effects of MSH' and cyclic AMP on microtubules and 10 nm filaments. Yale J. Bio. Med. 46, 337-360 (1973).
11. Vihinen PP, Pyrhönen SO, Kähäri VM: New prognostic factors and developing therapy of cutaneous melanoma. Ann. Med. 35(2), 66-78 (2003).
12. Bogdahn U, Apfel R, Hahn M et al.: Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 49, 5358-5363 (1989).
13. Blesch A, Bosserhoff AK, Apfel R et al.: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 54, 5695-5701 (1994).
14. Koehler MR, Bosserhoff A, von Beust G et al.: Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 35, 265-267 (1996).
15. Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R: MIA ('melanoma inhibitory activity'). Biological functions and clinical relevance in malignant melanoma. Hautarzt. 49(10), 762-769 (1998).
16. Bosserhoff AK: Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res. 18(6), 411-4116 (2005).
17. Vucetic B, Rogan SA, Hrabac P et al.: Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res. 18(3), 201-207 (2008).
18. Utikal J, Schadendorf D, Ugurel S: Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch. Dermatol. Res. 298, 469-477 (2007).
19. Lugovic L, Situm M, Buljan M, Poduje S, Sebetic K: Results of the determination of serum markers in patients with malignant melanoma. Coll. Antropol. 31 (1), 7-11 (2007).
20. Faries MB, Gupta RK, Ye X et al.: A Comparison of 3 tumor markers (MIA, TA90IC, S-100B) in stage III melanoma patients. Cancer Invest. 25(5), 285-293 (2007).
21. Garnier JP, Letellier S, Cassinat B et al.: Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S-100B, MIA and LDH in melanoma. Eur. J. Cancer 43(4), 816-821 (2007).
22. Neagu M, Constantin C, Manda G et al.: Metastatic Skin Melanoma Biomarkers. Presented at: The 2nd European Biomarkers Summit. Lisbon, Portugal, 16-18 October (2008).
23. Loppin M, Quillien V, Adamski H, Ollivier I, Garlantézec R, Chevrant-Breton J: Protéine S100 Béta et Melanoma Inhibitory Activity (MIA) sériques: étude prospective de leur valeur pour la détection précoce de métastases dans le mélanome. Ann. Dermatol.Vénéréol. 134 (6-7), 535-540 (2007).
24. Poser I, Rothhammer T, Dooley S, Weiskirchen R, Bosserhoff AK: Characterization of Sno expression in malignant melanoma. Int. J. Oncol. 26(5), 1411-1417 (2005)
25. Rothhammer T, Bosserhoff AK: Influence of melanoma inhibitory activity on transforming growth factor-β signaling in malignant melanoma. Melanoma Res. 16(4), 309-316 (2006).
26. Tímár J, Mészáros L, Ladányi A, Puskás LG, Rásó E: Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies. Cell Immunol. 244(2), 154-157 (2006).
27. Tímár J, Csuka O: Molecular diagnostics of malignant melanoma: molecular staging, minimal residual disease. Magy. Onkol. 47(1), 63-66 (2003).
28. Jimbow K, Lee SK, King MG et al.: Melanin pigments and melanosomal proteins as differentiation markers unique to normal and neoplastic melanocytes. J. Invest. Dermatol. 100, 259s-268s (1993).
29. Karnell R, Kagedal B, Lindholm C, Nilsoon B, Arstrand K, Ringborg U: The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res. 10, 363-369 (2000).
30. Tsao H, Nadiminti U, Sober A, Bigby M: A meta-analysis of RT-PCR for tyrosinase mRNA as a marker for circulating tumor cells in cutaneuos melanoma. Arch. Dermatol. 137, 325-330 (2001).
31. Kounalakis N, Goydos JS: Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management. Curr. Oncol. Rep. 7(5), 377-382 (2005).
32. Schittek B, Blaheta HJ, Ellwanger U, Garbe C: Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. Recent Results Cancer Res. 158, 93-104 (2001).
33. Prichard RS, Dijkstra B, McDermott EW, Hill AD, O'Higgins NJ: The role of molecular staging in malignant melanoma. Eur. J. Surg. Oncol. 29(4), 306-314 (2003).
34. Palmieri G, Ascierto PA, Perrone F et al.: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21(5), 767-773 (2003).
35. Quaglino P, Savoia P, Osella-Abate S, Bernengo MG: RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. Expert Rev. Mol. Diagn. 4(5), 727-741 (2004).
36. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J: Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J. Eur. Acad. Dermatol. Venereol. 22(1), 56-64 (2008).
37. Rorsman H, Rosengren AM, Rosengren E: Determination of 5-S-Cysteinyldopa in Melanomas with a Fluorimetric Method. Yale J. Bio. Med. 46, 516-522 (1973).
38. Wakamatsu K, Takasaki A, Kågedal B, Kageshita T, Ito S: Determination of eumelanin in human urine. Pigment Cell Res. 19(2),163-169 (2006).
39. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73(3), 629-636 (1994).
40. Horikoshi T, Ito S: Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression. J. Dermatol. 19(11), 809-813 (1992).
41. Hartleb J, Damm Y, Arndt R, Christophers E, Stockfleth E: Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction-high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. J. Chromatogr. B. Biomed. Sci. Appl. 727(1-2), 31-42 (1999).
42. Bánfalvi T, Édesné BM, Gyergye M et al.: Laboratory markers of melanoma progression. Hungarian Oncology 47, 89-104 (2003).
43. Sasaki Y, Shimizu H, Naka W, Takeshita E, Nishikawa T: Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients. Acta Dermatol. Venereol. 77(5), 379-381 (1997).
44. Hara H, Chino K, Kawanami T, Sameshima T, Morishima T: 5-S-cysteinyldopa in urine and tumors. J. Dermatol. 19(11), 806-808 (1992).
45. Hasegawa M, Takata M, Hatta N, Wakamatsu K, Ito S, Takehara K: Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res. 7(3), 243-251 (1997).
46. Ye Z, Kageshita T, Ishihara T, Ito S, Ono T: A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1). J. Dermatol. 22(5), 370-375 (1995).
47. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G: Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 57(22), 5073-5076 (1997).
48. Zhiqi S, Soltani MH, Bhat KM et al.: Human melastatin 1 (TRPM1) is regulated by MITF and produces multiple polypeptide isoforms in melanocytes and melanoma. Melanoma Res. 14(6), 509-516 (2004)
49. Xu XZ, Moebius F, Gill DL, Montell C: Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoforms. Proc. Natl Acad. Sci. USA 98(19), 10692-10697 (2001).
50. Deeds J, Cronin F, Duncan LM: Patterns of melastatin mRNA expression in melanocytic tumors. Hum. Pathol. 31(11), 1346-1356 (2000).
51. Duncan LM, Deeds J, Cronin FE et al.: Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol. 19(2), 568-576 (2001).
52. Hammock L, Cohen C, Carlson G et al.: Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J. Cutan. Pathol. 33(9), 599-607 (2006).
53. Coulie PG, Brichard V, Van Pel A et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180(1), 35-42 (1994).
54. Kawakami Y, Eliyahu S, Delgado CH et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91(9), 3515-3519 (1994).
55. Salio M, Cella M, Vermi W et al.: Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33(4), 1052-1062 (2003).
56. Adamina M, Bolli M, Albo F et al.: Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br. J. Cancer 90(1), 263-269 (2004).
57. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW: Immunohistochemical characteristics of melanoma. J. Cutan. Pathol. 35(5), 433-444 (2008).
58. Denat L, Larue L: Malignant melanoma and the role of the paradoxal protein Microphthalmia transcription factor. Bull. Cancer. 94(1), 81-92 (2007).
59. Hodgkinson CA, Moore KJ, Nakayama A et al.: Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74, 395-404 (1993).
60. Steingrimsson E, Moore KJ, Lamoreux ML et al.: Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat. Genet. 8, 256-263 (1994).
61. McGill GG, Horstmann M, Widlund HR et al.: Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109(6), 707-718 (2002).
62. Price ER, Ding HF, Badalian T et al.: Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. J. Biol. Chem. 273(29), 17983-17986 (1998)
63. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE: MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391(6664), 298-301 (1998)
64. Reed JA, Medrano EE: Recent advances in melanoma research. Front. Biosci. 11, 3003-3013 (2006).
65. Halaban R: Pigmentation in melanomas: changes manifesting underlying oncogenic and metabolic activities. Oncol. Res. 13(1), 3-8 (2002).
66. Price ER, Horstmann MA, Wells AG et al.: α-melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J. Biol. Chem. 273(49), 33042-33047 (1998).
67. Miller JA, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE: Transcriptional regulation of the melanoma prognostic marker melastatin (Trpm1) by Mitf in melanocytes and melanoma. Cancer Res. 64, 509-516 (2004).
68. Reed JA, Lin Q, Chen D, Mian IS, Medrano EE: SKI pathways inducing progression of human melanoma. Cancer Met. Rev. 24(2), 265-272 (2005).
69. Dorvault CC, Weilbaecher KN, Yee H et al.: Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens. Cancer 93(5), 337-343 (2001).
70. Vachtenheim J, Borovanský J: Microphthalmia transcription factor: a specific marker for malignant melanoma. Prague Med. Rep. 105(3), 318-324 (2004).
71. King R, Googe PB, Weilbaecher KN, Mihm MC Jr, Fisher DE: Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am. J. Surg. Pathol. 25(1), 51-57 (2001).
72. Takata M, Saida T: Genetic alterations in melanocytic tumors. J. Dermatol. Sci. 43(1), 1-10 (2006).
73. Vance KW, Goding CR: The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 17(4), 318-325 (2004).
74. Beyer C, Kaufmann K, Wehner F: Importance and function of the melanocyte-stimulating hormone in malignant melanoma. Importance of MSH. Dermatol. Monatsschr. 176(10), 589-596 (1990)
75. Eves PC, MacNeil S, Haycock JW: α-melanocyte stimulating hormone, inflammation and human melanoma. Peptides 27(2), 444-452 (2006).
76. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R: The melanocortin 1 receptor and the UV response of human melanocytes-a shift in paradigm. Photochem. Photobiol. 84(2), 501-508 (2008).
77. Schaffer JV, Bolognia JL: The melanocortin-1 receptor: red hair and beyond. Arch. Dermatol. 137(11), 1477-1485 (2001).
78. Millington GW: Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin. Exp. Dermatol. 31(3), 407-412 (2006).
79. Böhm M, Luger TA, Tobin DJ, García-Borrón JC: Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J. Invest. Dermatol. 126(9), 1966-1975 (2006).
80. Kadekaro AL, Kanto H, Kavanagh R, Abdel-Malek ZA: Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann. NY Acad. Sci. 994, 359-365 (2003).
81. Zhu N, Eves PC, Katerinaki E et al.: Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor α and suppressed by α melanocyte stimulating hormone. J. Invest. Dermatol. 119(5), 1165-1171 (2002).
82. Lekmine F, Salti GI: Induction of microphthalmia transcription factor (Mitf) by forskolin and stimulation of melanin release in UISO-Mel-6 cells. J. Surg. Res. 149(1), 27-30 (2008).
83. Fisher DE: Microphthalmia: a signal responsive transcriptional regulator in development. Pigment Cell Res. 13(8), 145-149 (2000).
84. Zhang W, Tsan R, Nam DH, Lu W, Fidler IJ: Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to melanotic by inhibition of AKT. Neoplasia 8(7), 543-550 (2006).
85. Miao Y, Quinn TP: α-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front. Biosci. 12, 4514-4524 (2007).
86. Hedley SJ, Gawkrodger DJ, Weetman AP et al.: α-melanocyte stimulating hormone inhibits tumour necrosis factor-α stimulated intercellular adhesion molecule-1 expression in normal cutaneous human melanocytes and in melanoma cell lines. Br. J. Dermatol. 138(3), 536-543 (1998).
87. Gupta RK, Morton DL: Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J. Clin. Lab. Anal. 6, 329-336 (1992).
88. Euhus DM, Gupta RK, Morton DL: Characterization of a 90-100kDa tumor-associated antigen in the sera of melanoma patients. Int. J. Cancer 45, 1065-1070 (1990).
89. Hellstrom I, Hellstrom KE, Sjogren HO, Warner GA: Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int. J. Cancer 7, 1-16 (1971).
90. Gupta RK: Circulating immune complexes in malignant melanoma. Dis. Markers 6, 81-96 (1988).
91. Chung MH, Gupta RK, Essner R, Ye W, Yee R, Morton DL: Serum TA90 immune complex assay can predict outcome after resection of thick ≥ 4 mm) primary melanoma and sentinel lymphadenectomy. Ann. Surg. Oncol. 9(2), 120-126 (2002).
92. Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL: Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann. Surg. Oncol. 7(3), 232-238 (2000)
93. DiFronzo LA, Gupta RK, Essner R et al.: Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J. Clin. Oncol. 20(15), 3242-3248 (2002).
94. Morton DL: Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Dev. Biol. (Basel). 116, 209-217 (2004).
95. Litvak DA, Gupta RK, Yee R, Wanek LA, Ye W, Morton DL: Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J. Am. Coll. Surg. 198(1), 27-35 (2004).
96. Kelley MC, Gupta RK, Hsuec EC et al.: Tumor associated TA90 immun complex assay predicts recurrence and survival after surgical treatment of stage I-II melanoma. J. Clin. Oncol. 19, 1176-1182 (2001).
97. Habal N, Gupta RK, Bilchik AJ, Johnson T, Morton DL: TA90-IC, a new marker for advanced colon cancer. Ann. Surg. Oncol. 7(5), 352-356 (2000).
98. Ruiter DJ, Herlyn M: Melanoma-stroma interactions and melanoma progression. J. Dtsch Dermatol. Ges. 1(10), 773-776 (2003).
99. Moore BW: A soluble protein characteristic of the nervous system. Biochem. Biophys. Res. Commun. 19, 739-744 (1965).
100. Bánfalvi T, Gergye M, Beczássy E, Gilde K, Ottó S: Role of S-100B protein in neoplasms and other diseases. Magy. Onkol. 48(1), 71-74 (2004).
101. Guo HB, StoVel-Wagner B, Bierwirth T, Mezger J, Klingmuller D: Clinical significance of serum S100 in metastatic malignant melanoma. Eur. J. Cancer 31A, 924-928 (1995).
102. Gaynor R, Irie R, Morton D, Herschmann H: S-100 protein is present in cultured human malignant melanomas. Nature 286, 400-401 (1980).
103. Schafer BW, Wicki R, Engelkamp D et al.: Isolation of a YAC clone covering a cluster of nine S-100 genes on a human chromosome 1q21 rationale for a new nomenclature of the S-100 calcium-binding protein family. Genomics 25, 638-643 (1995).
104. Baudier J, Gérard D: Ions binding to S-100 proteins: structural changes induced by calcium and zinc on S100a and S100b proteins. Biochemistry 22(14), 3360-3369 (1983).
105. Bonfrer JMG, Korse CM, Nieweg OE, Rankin EM: The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br. J. Cancer 77, 2210-2214 (1998).
106. Harpio R, Einarsson R: S-100 proteins as cancer biomarkers with focus on S-100B in malignant melanoma. Clin. Biochem. 37(7), 512-518 (2004).
107. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A: Long-term survival analysis in metastatic melanoma: serum S-100B is an independent prognostic marker and superior to LDH. Onkologie 31(7), 398-403 (2008).
108. Andrés R, Mayordomo JI, Visus C et al.: Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am. J. Clin. Oncol. 31(4), 335-339 (2008).
109. Smit LH, Korse CM, Hart AA et al.: Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur. J. Cancer 41(3), 386-392 (2005).
110. Ugurel S: Serum markers for melanoma. Hautarzt. 56(2), 173-184 (2005).
111. Böni R, Burg G, Doguoglu A et al.: Immunohistochemical histochemical localization of the Ca binding S-100 proteins in normal human skin and melanocytic lesions. Br. J. Dermatol. 137, 39-43 (1997).
112. Eng W, Tschen JA: Comparison of S-100 versus hematoxylin and eosin staining in evaluating dermal invasion and peripheral margins by desmoplastic malignant melanoma. Am. J. Dermatopathol. 22, 26-29 (2000).
113. Orchard GE: Comparison of immunohistochemical labelling of melanocyte differentation antibodies melan- A, tyrosinase and HMB 45 with NKIC3 and S-100 protein in evaluation of benign naevi and malignant melanoma. Histochem. J. 32, 475-481(2000).
114. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 51, 840-843 (1983).
115. Neuman HH, Patel A, Ishill N et al.: A single institution validation of the AJCC staging system for stage IV melanoma. Ann. Surg. Oncol. 15, 2034-2941 (2008).
116. Sirott MN, Bajorin DF, Wong GY et al.: Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72, 3091-3098 (1993).
117. Balch CM, Buzaid AC, Soong SJ et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648 (2001)
118. Balch CM, Soong SJ, Atkins MB et al.: An evidence-based staging system for cutaneous melanoma. Cancer J. Clin. 54(3), 131-149 (2004).
119. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL: Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J. Am. Acad. Dermatol. 51(3), 399-405 (2004).
120. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K: Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br. J. Cancer 91(4), 699-702 (2004).
121. Ishihara K, Saida T, Otsuka F, Yamazaki N: Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int. J. Clin. Oncol. 13(1), 33-41 (2008).
122. Bedikian AY, Johnson MM, Warneke CL et al.: Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 26(6), 624-633 (2008).
123. Khan MA, Andrews S, IsmaIL-Khan R et al.: Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control 13(3), 211-217 (2006).
124. Schmidt H, Bastholt L, Geertsen P et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer 93(3), 273-278 (2005).
125. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R: Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res. 15(3), 199-204 (2005).
126. Keilholz U, Martus P, Punt CJ et al.: Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin. Eur. J. Cancer 38(11), 1501-1511 (2002).
127. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN: Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188, 122-135 (2002).
128. Weber JS: Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. J. Invest. Dermatol. 128(12), 2750-2752 (2008).
129. Tas F, Oguz H, Argon A et al.: The value of serum levels of IL-6, TNF-α, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med. Oncol. 22(3), 241-246 (2005).
130. Murakami T, Cardones AR, Hwang ST: Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 36(2), 71-78. (2004).
131. Fang L, Lee VC, Cha E, Zhang H, Hwang ST: CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J. Leukoc. Biol. 84(4), 965-972 (2008).
132. Schutyser E, Su Y, Yu Y et al.: Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur. Cytokine Netw. 18(2), 59-70 (2007).
133. Quereux G, Pandolfino MC, Knol AC et al.: Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur. J. Dermatol. 17(4), 295-301 (2007).
134. Ménard C, Ghiringhelli F, Roux S et al.: Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin. Cancer Res. 14(16), 5242-5249 (2008).
135. Vence L, Palucka AK, Fay JW et al.: Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. PNAS 18(2), 59-70 (2007).
136. Gajewski TF: Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 12, 2326s-2330s (2006).
137. + nondendritic antigen-presenting cells by exposure of monocytes to IFN-α. J. Immunol. 181(5), 2999-3008 (2008).
138. Yurkovetsky ZR, Kirkwood JM, Edington HD et al.: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin. Cancer Res. 13(8), 2422-2428 (2007).
139. Dréau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL: Angiogenic and immune parameters during recombinant interferon-α2b adjuvant treatment in patients with melanoma. Oncol. Res. 12(5), 241-251 (2000).
140. Shah KV, Chien AJ, Yee C, Moon RT: CTLA-4 is a direct target of Wnt/ β-catenin signaling and is expressed in human melanoma tumors. J. Invest. Dermatol. 128(12), 2870-2879 (2008).
141. Slingluff CL Jr, Petroni GR, Olson W et al.: Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J. Clin. Oncol. 26(30), 4973-4980 (2008).
142. Gogas H, Ioannovich J, Dafni U et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354(7), 709-718 (2006).
143. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO: Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol. 46(5), 678-684 (2007).
144. Hendrix MJC, Seftor EA, Hess AR, Seftor REB: Vascular mimicry and tumour-cell plasticity. Lessons from melanoma. Nat. Rev. Cancer. 3, 411-421 (2003).
145. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK: Peritumour lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 64, 4400-4404 (2004).
146. Goydos JS, Gorski DH: Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin. Cancer Res. 9, 5962-5967 (2003).
147. Schietroma C, Cianfarani F, Lacal PM et al.: Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 98, 789-797 (2003).
148. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C: Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br. J. Dermatol. 156(4), 653-658 (2007).
149. Brennecke S, Deichmann M, Naeher H, Kurzen H: Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res. 15(6), 515-522 (2005).
150. Vihinen P, Kallioinen M, Vuoristo MS et al.: Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin. Exp. Metastasis 24(7), 567-574 (2007).
151. Ghosh S, Maity P: Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Int. Immunopharmacol. 7(13), 1598-15608 (2007).
152. Nikkola J, Vihinen P, Vuoristo M-S, Kellokumpu-Lehtinen P, Kahari V-M, Pyrhonen S: High serum levels of matrixmetalloproteinase-9 and matrixmetalloproteinase1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res. 11(14), 5158-5166 (2005).
153. Vihinen P, Koskivuo I, Syrjänen K, Tervahartiala T, Sorsa T, Pyrhönen S: Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 18(4), 268-273 (2008).
154. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E: Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med. Oncol. 25(4), 431-436, (2008).
155. Ros-Bullon MR, Sanchez Pedreno P, Martinez Liarte JH: Serum zinc levels are incerased in melanoma patients. Melanoma Res. 8, 273-277 (1998).
156. Ros-Bullon MR, Sanchez Pedreno P, Martinez Liarte JH: Serum ceruloplasmin in melanoma patients. Anticancer Res. 21, 629-632 (2001).
157. Volck B, Price PA, Johansen JS et al.: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians 110, 351-360 (1998).
158. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H: Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5), 1130-1139 (2006).
159. Miliotes G, Lyman GH, Cruse CW et al.: Evaluation of new putative tumor markers for melanoma. Ann. Surg. Oncol. 3, 558-563 (1996).
160. Buzaid AC, Sandler AB, Hayden CL et al.: Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int. J. Biol. Markers 9(4), 247-250 (1994).
161. Tofani A, Cioffi RP, Sciuto R et al.: S-100 and NSE as serum markers in melanoma. Acta Oncol. 36(7), 761-764 (1997).